Matthew White
Director of Finance/CFO chez APIAM ANIMAL HEALTH LIMITED
Fortune : 34 294 $ au 31/03/2024
Profil
Matthew White is currently the Chief Financial Officer at Apiam Animal Health Ltd.
since 2015.
Prior to this, he worked as a Finance Director at Merck Sharp & Dohme (Australia) Pty Ltd.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
APIAM ANIMAL HEALTH LTD.
0,08% | 30/06/2023 | 146 017 ( 0,08% ) | 34 294 $ | 31/03/2024 |
Postes actifs de Matthew White
| Sociétés | Poste | Début |
|---|---|---|
| APIAM ANIMAL HEALTH LIMITED | Director of Finance/CFO | 01/08/2015 |
Anciens postes connus de Matthew White
| Sociétés | Poste | Fin |
|---|---|---|
Merck Sharp & Dohme (Australia) Pty Ltd.
 Merck Sharp & Dohme (Australia) Pty Ltd. Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Sharp & Dohme (Australia) Pty Ltd. is an Australian research-intensive biopharmaceutical company committed to saving and improving lives. The private company is based in North Ryde, Australia and is dedicated to following the science to tackle some of the world's greatest health threats. MSD Australia has a long legacy of research in infectious disease and has been mobilizing its scientific expertise and experience to develop an effective response to the COVID-19 pandemic since it was first recognized. | Director of Finance/CFO | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| APIAM ANIMAL HEALTH LIMITED | Distribution Services |
| Entreprise privées | 1 |
|---|---|
Merck Sharp & Dohme (Australia) Pty Ltd.
Merck Sharp & Dohme (Australia) Pty Ltd. Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Sharp & Dohme (Australia) Pty Ltd. is an Australian research-intensive biopharmaceutical company committed to saving and improving lives. The private company is based in North Ryde, Australia and is dedicated to following the science to tackle some of the world's greatest health threats. MSD Australia has a long legacy of research in infectious disease and has been mobilizing its scientific expertise and experience to develop an effective response to the COVID-19 pandemic since it was first recognized. | Health Technology |
